Am­gen bows out of PhI­Ib tri­als test­ing bis­pe­cif­ic, fu­sion pro­tein for lu­pus

In a set­back to the grow­ing field of sys­temic lu­pus ery­the­mato­sus drug de­vel­op­ment, Am­gen is bow­ing out of two Phase IIb tri­als af­ter de­cid­ing its can­di­dates were un­like­ly to work.

Both tri­als, in­volv­ing two dif­fer­ent mol­e­cules, were stopped for fu­til­i­ty, Am­gen dis­closed in its quar­ter­ly re­port. Roz­iba­fusp al­fa (AMG 570) is an an­ti­body-pep­tide con­ju­gate that tar­gets in­ducible T cell cos­tim­u­la­tor lig­and (ICOSL) and B-cell ac­ti­vat­ing fac­tor (BAFF) in hopes of hit­ting both im­mune cell pop­u­la­tions; efavaleukin al­fa is an in­ter­leukin-2 (IL-2) mutein Fc fu­sion pro­tein.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER